

First Quarter 2019 Financial Results May 7, 2019

© 2019 Jazz Pharmaceuticals all rights reserved.

Forward-Looking Statements

"Safe Harbor" Statement Under the Private Securities Litigation Reform Act of 1995

This slide deck and the accompanying oral presentation contain forward-looking statements, including, but not limited to, statements related to Jazz Pharmaceuticals' future financial and operating results, including 2019 financial guidance and goals; the company's corporate development efforts; the company's growth strategy and expectations for growth; future product sales and volume; planned sales and marketing and related efforts; future inventory and supply challenges; planned, ongoing and future clinical trials and other product development activities, including clinical trial data read-outs, regulatory events such as the potential approval of the company's MAA for solriamfetol, and additional planned regulatory submissions; future product launches, including the anticipated launch of Sunosi in the U.S. and EU; the timing of such events and activities; and other statements that are not historical facts. These forward-looking statements are based on the company's current plans, objectives, estimates, expectations and intentions and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks and uncertainties associated with: maintaining or increasing sales of and revenue from Xyrem; effectively commercializing the company's other products and product candidates; the time-consuming and uncertain regulatory approval process, including the risk that the company's regulatory submissions, including the solriamfetol MAA, may not be approved by applicable regulatory authorities in a timely manner or at all; costly and time-consuming pharmaceutical product development and the uncertainty of clinical success, including risks related to failure or delays in initiating or completing clinical trials; protecting and enhancing the company's intellectual property rights; delays or problems in the supply or manufacture of the company's products and product candidates; complying with applicable U.S. and non-U.S. regulatory requirements; government investigations and other actions; obtaining and maintaining adequate coverage and reimbursement for the company's products; identifying and acquiring, in-licensing or developing additional products or product candidates, financing these transactions and successfully integrating acquired businesses; the ability to achieve expected future financial performance and results and the uncertainty of future tax and other provisions and estimates; and other risks and uncertainties affecting the company, including those described from time to time under the caption "Risk Factors" and elsewhere in Jazz Pharmaceuticals plc's Securities and Exchange Commission filings and reports (Commission File No. 001-33500), including the company's Annual Report on Form 10-K for the year ended December 31, 2018 and future filings and reports by the company, including the company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2019. Other risks and uncertainties of which the company is not currently aware may also affect the company's forward-looking statements and may cause actual results and the timing of events to differ materially from those anticipated. The forward-looking statements made in this slide deck and the accompanying oral presentation are made only as of the date hereof or as of the dates indicated in the forward-looking statements, even if they are subsequently made available by the company on its website or otherwise. The company undertakes no obligation to update or supplement any forward-looking statements to reflect actual results, new information, future events, changes in its expectations or other circumstances that exist after the date as of which the forward-looking statements were made.



1Q19 Conference Call

Bruce Cozadd Chairman and Chief Executive Officer	Overview
Matt Young Executive Vice President and Chief Financial Officer	Financial Update
Dan Swisher President and Chief Operating Officer	Q&A
Mike Miller Executive Vice President, U.S. Commercial	Q&A
Allen Yang, MD, PhD Head of Clinical Development and Acting Chief Medical Officer	Q&A
Jed Black, MD Senior Vice President, Sleep and CNS Medicine	Q&A



Growing R&D Pipeline

PRE-CLINICAL	PHASE 1	PHASE 2	PHASE 3	REGULATORY
Oxybate Once Nightly Formulation	Vyxeos + gemtuzumab ³ R/R AML or HMA Failure MDS	Defitelio Prevention of aGvHD	JZP-258 Cataplexy & EDS in narcolepsy	Solriamfetol EU EDS in OSA and Narcolepsy
CombiPlex Solid tumors candidate	Vyxeos + venetoclax ⁴ Low Intensity Dosing for unfit AML (Phase 1/2)	Defitelio ^₄ Treatment of TA-TMA	JZP-258 Idiopathic hypersomnia	
CombiPlex Hem/Onc exploratory activities	Vyxeos ^{3,4} Low Intensity Dosing for higher risk MDS	Defitelio ⁴ Prevention of CAR-T associated neurotoxicity	Defitelio Prevention of VOD	
Asparaginase ALL/other hematological malignancies	IMGN779 ¹ CD33+ AML	Vyxeos + venetoclax ³ <i>de novo</i> or R/R AML	Vyxeos ⁶ AML or HR-MDS (AML19)	
Recomb. Pegaspargase ¹ Hematological malignancies	IMGN632 ¹ CD123+ Hematological malignancies ⁵	Vyxeos ^{4,6} MDS	Vyxeos ⁶ AML or HR-MDS (AML18)	
Defitelio Exploratory activities		Vyxeos ⁶ R/R AML (COG)		
Exosome NRAS candidate ² Hematological malignancies				
Exosome STAT3 candidate ² Hematological malignancies				
Exosome-based candidates ² Solid tumors/Hematological malignancies				SLEEP HEMATOLOGY/ONCOLOGY

¹ Opt-in opportunity, ² Jazz & Codiak collaboration, ³ Jazz & MD Anderson Cancer Center collaboration study, ⁴ Planned , ⁵ Including AML and BPDCN, ⁶ Cooperative group study

1Q19 & Upcoming Events

	Hematology/Oncology	
Vyxeos	Defitelio	Erwinaze
 Secured final approved pricing in England, Wales, Scotland, Denmark & Netherlands Received positive health technology assessments in France, Italy & Germany Finalized protocol for Phase 1/2 study evaluating low-dose Vyxeos in combination with venetoclax in first- line unfit AML COG Phase 2 study of Vyxeos in younger patients with R/R AML accepted for oral presentation at ASCO Plan to initiate Phase 1 attenuated dose finding study in higher risk MDS patients in 2Q19 (MD Anderson collaboration) 	 Positive results from DEFIFrance, an observational, multi-center, post-marketing study of defibrotide, presented at EBMT meeting Received marketing approval for Defitelio in Brazil 1Q19 Conduct IA for pVOD Phase 3 study Complete enrollment in the Phase 2 prevention of aGvHD study Plan to initiate Phase 2 proof-of-concept study in CAR-T associated neurotoxicity in 2019 Plan to initiate Phase 2 study for the treatment of TA-TMA in 2019 Expect approval in Japan in 2019 	 1Q19 net sales increased due to higher availability of product compared to prior periods Expect limited product availability in 2Q19 and quarterly variability in 2019 based on timing and extent of supply disruptions


1Q19 & Upcoming Events

Xyrem JZP-258 Sunosi	
 Volume growth of 5% in 1Q19 compared to 1Q18 Average number of active patients increased to 14,575 in 1Q19, up 6% compared to 1Q18 Launched pediatric narcolepsy indication Announced positive top-line results from Phase 3 study in adult narcolepsy patients with cataplexy and EDS Expect pre-NDA meeting with FDA in 2019 Expect to submit data for presentation at fall 2019 medical meeting Goal to submit NDA as early as year-end Received FDA approval Mar 2019 Sales force expansion comp 2Q19 Expect to launch Sunosi in U following DEA scheduling decision which typically occu- within 90 days of FDA appro- Within 90 days of FDA appro- 	mpleted n U.S. ccurs proval



1Q19 Revenue Summary

\$ millions (unaudited)



In millions, except % (unaudited)	1Q18	4Q18	1Q19	Δ 1Q19 vs 4Q18	Δ 1Q19 vs 1Q18
Xyrem [®] (sodium oxybate) oral solution	\$317	\$375	\$368	(2)%	16%
Erwinaze [®] /Erwinase [®] (asparaginase <i>Erwinia</i> <i>chrysanthemi</i>)	51	24	61	151%	20%
Defitelio [®] (defibrotide sodium)/defibrotide	35	38	42	10%	18%
Vyxeos [®] (daunorubicin and cytarabine) liposome for injection	26	26	29	13%	10%
Other	12	5	4	(25)%	(70)%
Total Net Product Sales	441	467	503	8%	14%
Royalties and contract revenues	4	9	5	(47)%	29%
Total Revenues	\$445	\$476	\$508	7%	14%



Note: Amounts may not total due to rounding. Percentages calculated from amounts in thousands.

1Q19 Key Adjusted Line Items and Other Information¹


Adjusted In millions, except % (unaudited)	1Q18	4Q18	1Q19	Δ 1Q19 vs 4Q18	Δ 1Q19 vs 1Q18
Gross Margin	92.7%	94.7%	93.7%	(1.0) pp	1.0 pp
SG&A Expense % of Total Revenues	\$132 29.7%	\$142 29.8%	\$148 29.0%	4% (0.8) pp	12% (0.7) pp
R&D Expense % of Total Revenues	\$47 10.6%	\$51 10.8%	\$55 10.7%	6% (0.1) pp	15% 0.1 pp
Operating Income Margin	52.4%	54.2%	54.0%	(0.2) pp	1.6 pp
Effective Tax Rate ²	17.5%	11.7%	19.8%	8.1 pp	2.3 pp

Note: Amounts may not total due to rounding. Percentages calculated from amounts in thousands.


¹ These financial measures are presented entirely on a non-GAAP adjusted basis. Refer to the Appendix for more details on these non-GAAP adjusted financial measures, the most directly comparable GAAP reported financial measures and the related reconciliations between these financial measures. ² The 4Q18 effective tax rate was favorably impacted by a valuation allowance release.



1Q19 Financial Performance



Adjusted Net Income



Adjusted Net Income Per Diluted Share

Refer to the Appendix for reconciliations of GAAP reported to non-GAAP adjusted financial measures.



Cash and Debt

In millions (unaudited)	December 31, 2018	March 31, 2019
Cash, cash equivalents and investments	\$825	\$832
Total long-term debt (principal) ¹	\$1,801	\$1,793
Undrawn revolving credit	\$1,600	\$1,600
In millions	Three Months E	inded March 31,
(unaudited)	2018	2019
Cash flow from operations	\$167	\$202

¹ The carrying value of the company's total debt, as of December 31, 2018 and March 31, 2019, was \$1,596M and \$1,599M, respectively. The difference between principal and carrying values, at both dates, related to unamortized debt discount and debt issuance costs.



Share Repurchase Program¹


Share Repurchases	Dollar Amount Repurchased (in millions)	Shares Repurchased	Average Purchase Price Per Share
1Q19	\$111.2	857,988	\$129.66
2018	\$523.7	3,530,409	\$148.33
2017	\$98.8	704,014	\$140.34
4Q16	\$18.5	174,800	\$105.71
Program Total	\$752.2	5,267,211	\$142.81

Note: Amounts may not total due to rounding.

¹ Since November 2016, the company's board of directors authorized a new share repurchase program under which the company is authorized to repurchase a number of ordinary shares having an aggregate purchase price of up to \$1.02B, exclusive of any brokerage commissions. As of March 31, 2019, the remaining amount authorized under the share repurchase program was \$267.9M.



Strong Top and Bottom Line Growth While Investing for the Future



¹ 2014, 2015, 2016, 2017 and 2018 audited. ² G=Guidance. Guidance provided by Jazz Pharmaceuticals plc on and as of May 7, 2019. ³ CAGR calculations based on mid-point of guidance. ⁴ Reconciliations of GAAP net income to non-GAAP adjusted net income can be found in the Appendix at the end of this presentation.




2019 Full-Year Financial Guidance

In millions, except per share amounts and %	2019 Guidance ¹
Revenues	\$2,050 - \$2,130 ²
Total Net Product Sales	\$2,035 - \$2,110 ²
Xyrem Net Sales	\$1,530 - \$1,570
Erwinaze/Erwinase Net Sales	\$160 - \$195
Defitelio/defibrotide Net Sales	\$155 - \$180
Vyxeos Net Sales	\$120 - \$150
GAAP Gross Margin	94%
Non-GAAP Adjusted Gross Margin	94% ^{3,7}
GAAP SG&A Expense	\$702 - \$740
Non-GAAP Adjusted SG&A Expense	\$620 - \$650 ^{4,7}
GAAP R&D Expense	\$257 - \$326
GAAP Acquired In-Process Research and Development Expense	\$56
Non-GAAP Adjusted R&D Expense	\$235 - \$265 ^{5,7}
GAAP Effective Tax Rate	17% - 21%
Non-GAAP Adjusted Effective Tax Rate	17% - 19% ^{6,7}
GAAP Net Income	\$395 - \$495
Non-GAAP Adjusted Net Income	\$835 - \$875 ⁷
GAAP Net Income per Diluted Share	\$6.80 - \$8.50
Non-GAAP Adjusted Net Income per Diluted Share	\$14.30 - \$15.00 ⁷
Weighted-Average Ordinary Shares Used in Per Share Calculations	58

¹ Guidance provided by Jazz Pharmaceuticals plc as of May 7, 2019. ² Includes minimal net sales contribution from Sunosi in the U.S., assuming launch in mid-2019. ³ Excludes \$6-\$8M of share-based compensation expense from estimated GAAP gross margin. ⁴ Excludes \$82-\$90M of share-based compensation expense from estimated GAAP SG&A expenses. ⁵ Excludes \$0-\$34M of milestone payments and \$22-\$27M of share-based compensation expense from estimated GAAP reported and non-GAAP adjusted net income. ⁷ Refer to the Appendix for reconciliations of these non-GAAP adjusted guidance measures to the most directly comparable GAAP measures.





Appendix

Non-GAAP Financial Measures

To supplement Jazz Pharmaceuticals' financial results and guidance presented in accordance with GAAP, the company uses certain non-GAAP (also referred to as adjusted or non-GAAP adjusted) financial measures in this presentation and the accompanying tables. In particular, the company presents non-GAAP adjusted net income (and the related per share measure) and its line item components, as well as certain non-GAAP adjusted financial measures derived therefrom, including non-GAAP adjusted gross margin percentage, non-GAAP adjusted operating income margin percentage and non-GAAP adjusted effective tax rate. Non-GAAP adjusted net income (and the related per share measure) and its line item components exclude from reported GAAP net income (and the related per share measure) and its line item components exclude from reported GAAP net income (and the related per share measure) and its line item components that follow, and in the case of non-GAAP adjusted net income (and the related per share measure), adjust for the income tax effect of non-GAAP adjustments and the U.S. Tax Cuts and Jobs Act impact. In this regard, the components of non-GAAP adjusted net income, including non-GAAP cost of product sales, non-GAAP selling, general and administrative expenses and non-GAAP research and development expenses, are income statement line items prepared on the same basis as, and therefore components of, the overall non-GAAP adjusted net income measure.

The company believes that each of these non-GAAP financial measures provides useful supplementary information to, and facilitates additional analysis by, investors and analysts. In particular, the company believes that each of these non-GAAP financial measures, when considered together with the company's financial information prepared in accordance with GAAP, can enhance investors' and analysts' ability to meaningfully compare the company's results from period to period and to its forward-looking guidance, and to identify operating trends in the company's business. In addition, these non-GAAP financial measures are regularly used by investors and analysts to model and track the company's financial performance. Jazz Pharmaceuticals' management also regularly uses these non-GAAP financial measures internally to understand, manage and evaluate the company's business and to make operating decisions, and compensation of executives is based in part on certain of these non-GAAP financial measures. Because these non-GAAP financial measures are important internal measurements for Jazz Pharmaceuticals' management, the company also believes that these non-GAAP financial measures are useful to investors and analysts since these measures allow for greater transparency with respect to key financial metrics the company uses in assessing its own operating performance and making operating decisions.

These non-GAAP financial measures are not meant to be considered in isolation or as a substitute for comparable GAAP measures; should be read in conjunction with the company's condensed consolidated financial statements prepared in accordance with GAAP; have no standardized meaning prescribed by GAAP; and are not prepared under any comprehensive set of accounting rules or principles. In addition, from time to time in the future there may be other items that the company may exclude for purposes of its non-GAAP financial measures; and the company has ceased, and may in the future cease, to exclude items that it has historically excluded for purposes of its non-GAAP financial measures. Likewise, the company may determine to modify the nature of its adjustments to arrive at its non-GAAP financial measures. Because of the non-standardized definitions of non-GAAP financial measures, the non-GAAP financial measures as used by Jazz Pharmaceuticals in this presentation and the accompanying tables have limits in their usefulness to investors and may be calculated differently from, and therefore may not be directly comparable to, similarly titled measures used by other companies.



Reconciliation of GAAP Reported to Non-GAAP Adjusted Net Income


In millions, except per share amounts (unaudited)	1Q18	4Q18	1Q19
GAAP reported net income	\$ 46.0	\$ 159.5	\$ 85.2
Intangible asset amortization	53.0	46.5	56.9
Share-based compensation expense	24.3	26.7	27.6
Loss contingency	57.0		
Upfront and milestone payments	11.0		56.0
Non-cash interest expense	10.6	11.3	11.1
Income tax effect of above adjustments	(19.5)	(13.8)	(23.6)
U.S. Tax Cuts and Jobs Act impact		(10.3)	
Non-GAAP adjusted net income	\$ 182.4	\$ 220.0	\$ 213.2
GAAP reported net income per diluted share	\$ 0.75	\$ 2.64	\$ 1.47
Non-GAAP adjusted net income per diluted share	\$ 2.98	\$ 3.64	\$ 3.67
Weighted-average ordinary shares used in diluted per share calculations	61.2	60.4	58.1



Note: Amounts may not total due to rounding.

Reconciliations of GAAP Reported to Non-GAAP Adjusted Information Certain Line Items and Other Information

		1Q18			4Q18			1Q19	
In millions, except per share amounts and % (unaudited)	GAAP Reported	Adjustments	Non-GAAP Adjusted	GAAP Reported	Adjustments	Non-GAAP Adjusted	GAAP Reported	Adjustments	Non-GAAP Adjusted
Product sales, net	\$ 440.8	\$	\$ 440.8	\$ 467.3	\$	\$ 467.3	\$ 503.3	\$	\$ 503.3
Total revenues	444.6		444.6	476.5		476.5	508.2		508.2
Cost of product sales	33.9	(1.7) ^(a)	32.2	26.3	(1.6) ^(a)	24.7	33.5	(1.7) ^(a)	31.8
% of Product sales, net	7.7%		7.3%	5.6%		5.3%	6.7%		6.3%
Gross margin ^(b)	92.3%		92.7%	94.4%		94.7%	93.3%		93.7%
Selling, general and administrative	207.2	(75.2) ^(c)	132.0	161.9	(19.8) ^(c)	142.1	167.9	(20.4) ^(c)	147.6
% of Total revenues	46.6%		29.7%	34.0%		29.8%	33.0%		29.0%
Research and development	62.7	(15.4) ^(d)	47.3	56.7	(5.4) ^(d)	51.3	60.1	(5.5) ^(d)	54.6
% of Total revenues	14.1%		10.6%	11.9%		10.8%	11.8%		10.7%
Intangible asset amortization	53.0	(53.0)		46.5	(46.5)		56.9	(56.9)	
Acquired in-process research and development							56.0	(56.0)	
Operating income margin ^(e)	1 9.7%		52.4%	38.8%		54.2%	26.3%		54.0%
Interest expense, net	20.6	(10.6) ^(f)	10.0	17.9	(11.3) ^(f)	6.6	17.9	(11.1) ^(f)	6.8
Foreign exchange loss	1.7		1.7	1.7		1.7	0.6		0.6
Income before income tax provision and equity in loss of investees	65.5	155.9 ^(g)	221.4	165.5	84.6 ^(g)	250.0	115.2	151.6 ^(g)	266.8
Income tax provision	19.1	19.5 ^(h)	38.7	5.1	24.1 ^(h)	29.2	29.1	23.6 ^(h)	52.7
Effective tax rate ⁽ⁱ⁾	29.2%		17.5%	3.1%		11.7%	25.3%		19.8%
Equity in loss of investees	0.3		0.3	0.8		0.8	0.9		0.9
Net income	\$ 46.0	\$ 136.4 ^(j)	\$ 182.4	\$ 159.5	\$ 60.5 ^(j)	\$ 220.0	\$ 85.2	\$ 128.0 ^(j)	\$ 213.2
Net income per diluted share	\$ 0.75		\$ 2.98	\$ 2.64		\$ 3.64	\$ 1.47		\$ 3.67





Explanation of Adjustments to Above Reconciliation Table

Explanation of Adjustments and Certain Line Items (In millions):

- (a) Share-based compensation expense of \$1.7, \$1.6 and \$1.7 for 1Q18, 4Q18 and 1Q19, respectively.
- (b) Net of product sales, net and cost of product sales divided by product sales, net.
- (c) Share-based compensation expense of \$18.2, \$19.8, \$20.4, and loss contingency of \$57.0, \$0, \$0 for 1Q18, 4Q18 and 1Q19, respectively.
- (d) Upfront and milestone payments of \$11.0, \$0 and \$0 and share-based compensation expense of \$4.4, \$5.4 and \$5.5 for 1Q18, 4Q18 and 1Q19, respectively.
- (e) Income from operations divided by total revenues.
- (f) Non-cash interest expense associated with debt discount and debt issuance costs.
- (g) Sum of adjustments (a), (c), (d) and (f), plus the adjustment for intangible asset amortization and acquired in-process research and development, as applicable, for the respective quarter.
- (h) Income tax adjustments related to the income tax effect of adjustments between GAAP reported and non-GAAP adjusted net income and the impact of the U.S. Tax Cuts and Jobs Act.
- (i) Income tax provision divided by income before income tax provision and equity in loss of investees.
- (j) Net of adjustments (g) and (h).



Reconciliation of GAAP Reported to Non-GAAP Adjusted Net Income

In millions, except per share amounts (unaudited)	2014	2015	2016	2017	2018
GAAP net income ¹	\$ 58.4	\$ 329.5	\$ 396.8	\$ 487.8	\$ 447.1
Intangible asset amortization	126.6	98.2	102.0	152.1	201.5
Share-based compensation expense	69.6	91.6	98.8	106.9	102.4
Estimated loss contingency					57.0
Impairment charges and disposal costs	39.4	31.5			44.0
Upfront and milestone payments	202.6	25.0	23.8	101.5	11.0
Transaction and integration related costs	28.8	18.2	13.6		
Acquisition accounting inventory fair value step-up adjustments	10.5				
Expenses related to certain legal proceedings and restructuring	1.9	1.6	6.1	6.0	
Non-cash interest expense	13.7	22.7	22.1	30.0	44.0
Loss on extinguishment and modification of debt		16.8	0.6		
Income tax effect of above adjustments	(53.8)	(39.6)	(36.7)	(58.8)	(60.9)
U.S. Tax Cuts and Jobs Act impact				(148.8)	(7.5)
Amount attributable to noncontrolling interests	(1.5)				
Non-GAAP adjusted net income	\$ 496.3	\$ 595.5	\$ 627.2	\$ 676.7	\$ 838.6
GAAP net income per diluted share ¹	\$ 0.93	\$ 5.23	\$ 6.41	\$ 7.96	\$ 7.30
Non-GAAP adjusted net income per diluted share	\$ 7.93	\$ 9.45	\$ 10.14	\$ 11.04	\$ 13.70
Neighted-average ordinary shares used in diluted per share calculation	62.6	63.0	61.9	61.3	61.2

Note: Amounts may not total due to rounding. ¹2014, 2015, 2016, 2017 and 2018 audited.



Reconciliation of GAAP SG&A and R&D to Non-GAAP Adjusted SG&A and R&D

In millions, except per share amounts (unaudited)	2014	2015	2016	2017	2018	2019G
GAAP SG&A and R&D expense ¹	\$ 491.3	\$ 584.4	\$ 665.2	\$ 742.6	\$ 910.1	\$ 959 – 1,066
Share-based compensation expense	(67.3)	(88.0)	(94.3)	(101.1)	(95.8)	(104) – (117)
Loss contingency					(57.0)	
Disposal costs					(1.1)	
Upfront and milestone payments		(25.0)		(18.5)	(11.0)	0 - (34)
Expenses related to certain legal proceedings and restructuring	(1.9)	(1.1)	(6.0)	(6.0)		
Transaction and integration related costs	(28.8)	(18.2)	(13.6)			
Non-GAAP adjusted SG&A and R&D expense	\$ 393.3	\$ 452.1	\$ 551.3	\$ 617.0	\$ 745.3	\$ 855 - 915

Note: Amounts may not total due to rounding. ¹2014, 2015, 2016, 2017 and 2018 audited.



Reconciliation of GAAP to Non-GAAP Adjusted 2019 Financial Guidance

In millions, except per share amounts (unaudited)	2019 Guidance ¹
GAAP net income	\$395 - \$495
Intangible asset amortization*	240 - 260
Share-based compensation expense	110 – 125
Upfront and milestone payments	56 - 90
Non-cash interest expense	40 - 50
Income tax effect of above adjustments	(75) – (95)
Non-GAAP adjusted net income	\$835 - \$875
GAAP net income per diluted share	\$6.80 - \$8.50
Non-GAAP adjusted net income per diluted share	\$14.30 - \$15.00
Weighted-average ordinary shares used in per share calculations	58

 $^{\rm 1}$ Guidance provided by Jazz Pharmaceuticals plc as of May 7, 2019. $^{\rm *}$ Updated May 7, 2019.



Glossary of Abbreviations

aGvHD = Acute Graft-vs-Host Disease ALL = Acute Lymphoblastic Leukemia AML = Acute Myeloid Leukemia ASCO = American Society of Clinical Oncology BPDCN = Blastic Plasmacytoid Dendritic Cell Neoplasm CAGR = Compound Annual Growth Rate CAR-T = Chimeric Antigen Receptor T-cell Therapy COG = Children's Oncology Group DEA = U.S. Drug Enforcement Administration EDS = Excessive Daytime Sleepiness EBMT = European Society for Blood and Marrow Transplant EU = European Union FDA = U.S. Food and Drug Administration GAAP = U.S. Generally Accepted Accounting Principles HMA = Hypomethylating Agent HR-MDS = High-Risk MDS IA = Interim Analysis IMGN = ImmunoGen MAA = Marketing Authorization Application MDS = Myelodysplastic Syndrome NDA = New Drug Application OSA = Obstructive Sleep Apnea pVOD = Prevention of Hepatic Veno-occlusive Disease R/R = Relapsed/Refractory TA-TMA = Transplant Associated Thrombotic Microangiopathy VOD = Hepatic Veno-occlusive Disease

